Therapeutic potential of green tea in nonalcoholic fatty liver disease
- PMID: 22221215
- DOI: 10.1111/j.1753-4887.2011.00440.x
Therapeutic potential of green tea in nonalcoholic fatty liver disease
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a constellation of progressive liver disorders that are closely related to obesity, diabetes, and insulin resistance and may afflict over 70 million Americans. NAFLD may occur as relatively benign, nonprogressive liver steatosis, but in many individuals it may progress in severity to nonalcoholic steatohepatitis, fibrosis, cirrhosis, and liver failure or hepatocellular carcinoma. No validated treatments currently exist for NAFLD except for weight loss, which has a poor long-term success rate. Thus, dietary strategies that prevent the development of liver steatosis or its progression to nonalcoholic steatohepatitis are critically needed. Green tea is rich in polyphenolic catechins that have hypolipidemic, thermogenic, antioxidant, and anti-inflammatory activities that may mitigate the occurrence and progression of NAFLD. This review presents the experimental evidence demonstrating the hepatoprotective properties of green tea and its catechins and the proposed mechanisms by which these targeted dietary agents protect against NAFLD.
© 2012 International Life Sciences Institute.
Similar articles
-
Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment.Dig Dis. 2012;30(2):158-62. doi: 10.1159/000336669. Epub 2012 Jun 20. Dig Dis. 2012. PMID: 22722431 Review.
-
Nonalcoholic fatty liver disease.Minerva Med. 2008 Dec;99(6):583-93. Minerva Med. 2008. PMID: 19034256 Review.
-
Anti-inflammatory activities of green tea catechins along the gut-liver axis in nonalcoholic fatty liver disease: lessons learned from preclinical and human studies.J Nutr Biochem. 2020 Nov;85:108478. doi: 10.1016/j.jnutbio.2020.108478. Epub 2020 Aug 12. J Nutr Biochem. 2020. PMID: 32801031 Review.
-
Nonalcoholic fatty liver disease: from clinical recognition to treatment.Expert Rev Gastroenterol Hepatol. 2008 Feb;2(1):59-79. doi: 10.1586/17474124.2.1.59. Expert Rev Gastroenterol Hepatol. 2008. PMID: 19072371 Review.
-
Treating nonalcoholic fatty liver disease.Liver Int. 2007 Nov;27(9):1157-65. doi: 10.1111/j.1478-3231.2007.01567.x. Liver Int. 2007. PMID: 17919226 Review.
Cited by
-
TRPV1 activation prevents nonalcoholic fatty liver through UCP2 upregulation in mice.Pflugers Arch. 2012 Apr;463(5):727-32. doi: 10.1007/s00424-012-1078-y. Epub 2012 Mar 7. Pflugers Arch. 2012. PMID: 22395410
-
Tea intake and non-alcoholic fatty liver disease risk: A two-sample Mendelian randomization study.Metabol Open. 2024 Sep 24;24:100322. doi: 10.1016/j.metop.2024.100322. eCollection 2024 Dec. Metabol Open. 2024. PMID: 39399721 Free PMC article.
-
Chemopreventive potential of green tea catechins in hepatocellular carcinoma.Int J Mol Sci. 2015 Mar 17;16(3):6124-39. doi: 10.3390/ijms16036124. Int J Mol Sci. 2015. PMID: 25789501 Free PMC article. Review.
-
Lycium barbarum polysaccharides protect rat liver from non-alcoholic steatohepatitis-induced injury.Nutr Diabetes. 2013 Jul 22;3(7):e81. doi: 10.1038/nutd.2013.22. Nutr Diabetes. 2013. PMID: 23877747 Free PMC article.
-
Green Tea Extract Treatment in Obese Mice with Nonalcoholic Steatohepatitis Restores the Hepatic Metabolome in Association with Limiting Endotoxemia-TLR4-NFκB-Mediated Inflammation.Mol Nutr Food Res. 2019 Dec;63(24):e1900811. doi: 10.1002/mnfr.201900811. Epub 2019 Oct 9. Mol Nutr Food Res. 2019. PMID: 31574193 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical